Cobalis Corporation
COBALIS COMPANY NEWS 2007

The following are recent important news releases by and about Cobalis, and its premier allergy prevention product PreHistin™:

Note: You will need Adobe Acrobat Reader installed to view the document. Click here to download Adobe Acrobat Reader.

Date   Description Downloads
08/27/07   Allergy Patients Treated with PreHistin Had Rise in Ragweed IgE Antibodies Blunted During Pollen Season   e Acrobat pdf file
08/02/07   Cobalis Reports PreHistin Demonstrates Significant Potential for Treatment of Vitamin B12 Deficiency   e Acrobat pdf file
07/06/07   Cobalis Reports Phase III Trial Results for PreHistin™ in Seasonal Allergic Rhinitis   e Acrobat pdf file
05/31/07   Cobalis Announces Delay in Reporting of Phase III Trial Results for PreHistin™
in Seasonal Allergic Rhinitis		   e Acrobat pdf file
04/30/07   Cobalis Expects to Report Phase III Top-LIne Results in May   e Acrobat pdf file
03/29/07   Cobalis Locks Database for Pivotal Twin Phase III Trials of PreHistin in Seasonal Allergic Rhinitis   e Acrobat pdf file
03/22/07   Cobalis Completes Funding; Expects Top-Line Phase III Trial Results for PreHistin™ in April 2007   e Acrobat pdf file
02/28/07   Cobalis’ Mexican Patent for PreHistin™ Allowed   e Acrobat pdf file
02/22/07   Cobalis Announces Second Closing in $3.85 Million Funding   e Acrobat pdf file
02/20/07   Cobalis Appoints Three Pharmaceutical Industry Executives to Board   e Acrobat pdf file
 

IMPORTANT NOTICE:
The FDA has not completed evaluation of PreHistin™, and the information and statements contained in this web site are intended for informational purposes only. They are not meant to imply a cure or approved treatment for any disease or condition. You are encouraged to consult your physician for any healthcare questions or concerns you may have about your allergies.